DE69637480T2 - Bioaktive il-12 fusionsproteine - Google Patents
Bioaktive il-12 fusionsproteine Download PDFInfo
- Publication number
- DE69637480T2 DE69637480T2 DE69637480T DE69637480T DE69637480T2 DE 69637480 T2 DE69637480 T2 DE 69637480T2 DE 69637480 T DE69637480 T DE 69637480T DE 69637480 T DE69637480 T DE 69637480T DE 69637480 T2 DE69637480 T2 DE 69637480T2
- Authority
- DE
- Germany
- Prior art keywords
- subunit
- linker
- cells
- dna
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/385,335 US5891680A (en) | 1995-02-08 | 1995-02-08 | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
PCT/US1996/001787 WO1996024676A1 (en) | 1995-02-08 | 1996-02-07 | Bioactive fusion proteins and pre-existing tumor therapy |
US385335 | 1999-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69637480D1 DE69637480D1 (de) | 2008-05-15 |
DE69637480T2 true DE69637480T2 (de) | 2009-04-09 |
Family
ID=23520989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69637480T Expired - Fee Related DE69637480T2 (de) | 1995-02-08 | 1996-02-07 | Bioaktive il-12 fusionsproteine |
Country Status (11)
Country | Link |
---|---|
US (1) | US5891680A (es) |
EP (1) | EP0815245B1 (es) |
JP (2) | JP3919220B2 (es) |
AT (1) | ATE391181T1 (es) |
AU (1) | AU701918B2 (es) |
DE (1) | DE69637480T2 (es) |
DK (1) | DK0815245T3 (es) |
ES (1) | ES2302565T3 (es) |
MX (1) | MX9706050A (es) |
PT (1) | PT815245E (es) |
WO (1) | WO1996024676A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023639A1 (fr) * | 1995-12-22 | 1997-07-03 | Toray Industries, Inc. | Procede de production de proteines fusionnees biologiquement actives |
WO1998012338A1 (en) * | 1996-09-21 | 1998-03-26 | Viromedica Pacific Limited | Improved retroviral vectors for gene therapy |
CA2268365A1 (en) * | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Il-12 gene expression and delivery systems and uses |
JP2001503258A (ja) * | 1996-10-18 | 2001-03-13 | バレンティス・インコーポレーテッド | 遺伝子発現および搬送系および用途 |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
CA2265505C (en) * | 1997-05-16 | 2009-09-08 | Toray Industries, Inc. | An immune disease remedy, treatment method and preventive agent and method for dogs and cats |
CO4810232A1 (es) * | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
MXPA00010070A (es) * | 1998-04-15 | 2004-03-10 | Lexigen Pharm Corp | Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis. |
WO2000014257A1 (en) * | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
DE19919148A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
AU6094100A (en) * | 1999-07-13 | 2001-01-30 | Heska Corporation | Fc epsilon receptor-luminescence inducing protein chimeric nucleic acid molecules, fusion proteins and uses thereof |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
EP1731531B1 (en) | 1999-08-09 | 2012-05-30 | Merck Patent GmbH | Multiple cytokine-antibody complexes |
AU778611B2 (en) * | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
EP1905832A3 (en) | 1999-09-09 | 2009-09-09 | Schering Corporation | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
AU7645700A (en) * | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
PL206701B1 (pl) * | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US20030235548A1 (en) * | 2002-06-12 | 2003-12-25 | L'oreal | Cosmetic composition for care and/or treatment and/or makeup of the emulsion type structured with silicone polymers |
MXPA05006384A (es) * | 2002-12-17 | 2005-08-29 | Merck Patent Gmbh | Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2. |
US8420087B2 (en) * | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
EA016022B1 (ru) | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Выделенное антитело млекопитающего против il-12 и способ изменения его активности |
US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
EP1966238B1 (en) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40 variants with improved stability |
RU2012123145A (ru) | 2009-11-05 | 2013-12-10 | Проекто Де Биомедисина Сима, С.Л. | Генный конструкт (варианты), вектор и рекомбинантный вирусный геном на его основе, вирион, их фармацевтическая композиция, способ in vitro экспрессии полинуклеотида в клетке печеночной природы, лекарственное средство, способ лечения заболевания печени (варианты), индуцируемый двунаправленный оператор-промотор |
GEP20196976B (en) | 2013-03-14 | 2019-06-10 | Sloan Kettering Cancer Center Memorial | Newcastle disease viruses and uses thereof |
EP4119662A1 (en) | 2013-05-10 | 2023-01-18 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
EP3441084A1 (en) | 2014-02-27 | 2019-02-13 | Viralytics Limited | Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer |
US11365230B2 (en) | 2015-11-09 | 2022-06-21 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
EP4186518A1 (en) | 2016-05-18 | 2023-05-31 | ModernaTX, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
US11421010B2 (en) * | 2016-10-07 | 2022-08-23 | Board Of Regents, The University Of Texas System | T cells expressing membrane-anchored IL-12 for the treatment of cancer |
CN110785435B (zh) | 2017-03-06 | 2024-01-23 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
CN108686202A (zh) | 2017-04-06 | 2018-10-23 | 张晋宇 | 肿瘤免疫疗法 |
JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
US20210139601A1 (en) * | 2017-05-25 | 2021-05-13 | The Broad Institute, Inc. | Lymphocyte antigen cd5-like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer agonists and methods of use thereof |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
CN109796534B (zh) * | 2017-11-16 | 2021-08-10 | 北京比洋生物技术有限公司 | 抗il-17抗体/tnfr ecd融合蛋白及其用途 |
US11578124B2 (en) | 2018-05-18 | 2023-02-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-IL12/IL23 antibody |
FI3883606T3 (fi) | 2018-09-24 | 2023-09-07 | Janssen Biotech Inc | Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
CN111848810A (zh) * | 2019-04-28 | 2020-10-30 | 张晋宇 | 一种蛋白质分子及其用途 |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
WO2020255010A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
CN112210014B (zh) * | 2019-07-12 | 2022-10-11 | 北京科诺科服生物科技有限公司 | 一种用于治疗动物肿瘤的融合蛋白及组合物 |
KR20240015033A (ko) * | 2022-07-25 | 2024-02-02 | 충남대학교산학협력단 | 인터루킨-7 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
JP2893653B2 (ja) * | 1988-11-10 | 1999-05-24 | ジェネティックス・インスティテュート・インコーポレイテッド | ナチュラルキラー細胞刺激因子 |
ATE366311T1 (de) * | 1989-12-22 | 2007-07-15 | Hoffmann La Roche | Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür |
ATE145428T1 (de) * | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
EP0642585B1 (en) * | 1992-05-18 | 2005-12-28 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
WO1994013806A1 (en) * | 1992-12-11 | 1994-06-23 | The Dow Chemical Company | Multivalent single chain antibodies |
IT1270866B (it) * | 1993-03-10 | 1997-05-13 | Eniricerche Spa | Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis |
ZA942206B (en) * | 1993-04-01 | 1994-10-31 | Amgen Inc | Biologically active polypeptide fusion dimers |
US5501962A (en) * | 1993-06-21 | 1996-03-26 | G. D. Searle & Co. | Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same |
US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
CH687795C1 (fr) * | 1994-05-07 | 2001-05-15 | Omega Sa | Piece d'horlogerie mecanique pourvue d'un tourbillon. |
US5650490A (en) * | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
-
1995
- 1995-02-08 US US08/385,335 patent/US5891680A/en not_active Expired - Fee Related
-
1996
- 1996-02-07 WO PCT/US1996/001787 patent/WO1996024676A1/en active Application Filing
- 1996-02-07 ES ES96905439T patent/ES2302565T3/es not_active Expired - Lifetime
- 1996-02-07 DE DE69637480T patent/DE69637480T2/de not_active Expired - Fee Related
- 1996-02-07 AU AU49198/96A patent/AU701918B2/en not_active Ceased
- 1996-02-07 AT AT96905439T patent/ATE391181T1/de not_active IP Right Cessation
- 1996-02-07 EP EP96905439A patent/EP0815245B1/en not_active Expired - Lifetime
- 1996-02-07 JP JP52444996A patent/JP3919220B2/ja not_active Expired - Fee Related
- 1996-02-07 MX MX9706050A patent/MX9706050A/es not_active IP Right Cessation
- 1996-02-07 PT PT96905439T patent/PT815245E/pt unknown
- 1996-02-07 DK DK96905439T patent/DK0815245T3/da active
-
2006
- 2006-08-21 JP JP2006224729A patent/JP2006314332A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2302565T3 (es) | 2008-07-16 |
WO1996024676A1 (en) | 1996-08-15 |
JP2006314332A (ja) | 2006-11-24 |
EP0815245A1 (en) | 1998-01-07 |
ATE391181T1 (de) | 2008-04-15 |
DK0815245T3 (da) | 2008-07-21 |
MX9706050A (es) | 1997-11-29 |
AU701918B2 (en) | 1999-02-11 |
EP0815245B1 (en) | 2008-04-02 |
JP3919220B2 (ja) | 2007-05-23 |
PT815245E (pt) | 2008-07-09 |
DE69637480D1 (de) | 2008-05-15 |
AU4919896A (en) | 1996-08-27 |
JPH10513362A (ja) | 1998-12-22 |
US5891680A (en) | 1999-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69637480T2 (de) | Bioaktive il-12 fusionsproteine | |
DE60036552T2 (de) | Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen | |
JP2688539B2 (ja) | ほ乳類サイトカイン、il―11 | |
DE69434750T2 (de) | Inhibierung des wachstums von ausgewählten tumoren mit rekombinanten viren-vektoren | |
DE69735643T2 (de) | IL12 zur Gentherapie der Tumoren | |
DE69129990T3 (de) | Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor | |
DE69636938T2 (de) | HYBRID AUS INTERFERON-alpha UND IMMUNGLOBULIN Fc-FRAGMENT VERBUNDEN DURCH EIN NICHT IMMUNOGENES PEPTID | |
DE60025832T2 (de) | Mehrere zytokin-antikörper komplexen | |
DE69635675T2 (de) | Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor | |
DE102005055128B4 (de) | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor | |
LV10790B (en) | A process for the preparation of antibodies | |
SK150596A3 (en) | Agonists and antagonists of human interleukin-10 | |
DE69734096T2 (de) | Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren | |
WO2002026827A1 (en) | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules | |
DE10248141B4 (de) | Nukleinsäuren und deren Verwendung für die Gentherapie | |
KR20180052103A (ko) | Nkx3.2 단편 및 이를 함유하는 약학 조성물 | |
DE60026588T2 (de) | Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus | |
CA2131709C (en) | Immune-enhancing agent for therapeutic use in immunocompromised hosts | |
DE69535288T2 (de) | Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren | |
DE69828414T2 (de) | Mukosale zytotoxische t-lymphozytenantwort | |
DE602004011061T2 (de) | Erhöhte t-zell tumor-eindringung durch light- mutanten | |
DE60029117T2 (de) | DNA Sequenzen zur Erhöhung der Futterausbeute und der Wachstumsrate bei Schweinen | |
EP0684842B1 (fr) | Composition pour le traitement de tumeurs et l'immunisation d'organismes a l'encontre de tumeurs | |
DE602004001395T2 (de) | Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon | |
EP1123392B1 (de) | Das gen prv-1 und dessen verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |